GlassScriptPhysician profile
Adam C Nader
NPI 1922394998
$5,652.26
in general payments reported to CMS, 2019-2025
18 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $387 · 2021: $912 · 2022: $900 · 2023: $1,014 · 2024: $666 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,440.78 | 2019-2025 | Gallant, Mitraclip, Assurity |
| Medtronic, INC. | $1,941.30 | 2021-2025 | Mycarelink, Micra, Linq II |
| Astellas Pharma US INC | $223.57 | 2019 | |
| Atricure, INC. | $177.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $167.16 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $140.04 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $127.84 | 2019-2025 | Eliquis, Camzyos |
| Braemar Manufacturing, LLC | $93.75 | 2019 | |
| Boston Scientific Corporation | $75.57 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.43 | 2025 | Jardiance |
| Amgen INC. | $46.05 | 2023-2024 | Repatha |
| Pfizer INC. | $25.24 | 2019 | |
| Kestra Medical Technology Services, INC. | $24.06 | 2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $22.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.21 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $19.12 | 2021 | |
| Heartflow, INC. | $18.71 | 2024 | |
| Amarin Pharma, INC. | $18.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.